Estrogen levels in different birth control pills
Pro Research Analysisby 
Searched over 200M research papers
Estrogen Content in Birth Control Pills: Historical and Modern Formulations
Birth control pills have evolved significantly since their introduction, especially regarding estrogen content. Early oral contraceptives contained high doses of estrogen, often 100 micrograms (µg) or more of ethinyl estradiol (EE), but modern pills now typically contain 35 µg or less, with some formulations as low as 15–20 µg EE per pill 2348. This reduction aims to minimize side effects and health risks, such as blood clots, while maintaining contraceptive effectiveness 3468.
Types of Birth Control Pills and Estrogen Levels
Monophasic, Biphasic, and Triphasic Pills
- Monophasic pills deliver the same dose of estrogen and progestin in each active pill. Most modern monophasic pills contain 20–35 µg of EE 234.
- Biphasic and triphasic pills vary the hormone doses throughout the cycle. Some sequential (biphasic) pills use a combination of estrogen and progestin in the first half of the cycle, with estrogen doses as low as 0.05 mg (50 µg) per day . Triphasic pills further adjust hormone levels to more closely mimic the natural menstrual cycle .
Ultra-Low Dose Pills
Recent developments have introduced "ultra-low dose" pills, such as those containing 15 µg EE combined with 60 µg gestodene. These are the lowest estrogen doses available and are designed to further reduce side effects and cardiovascular risks, though they may be associated with higher rates of irregular bleeding .
Extended-Cycle Pills
Extended-cycle pills, such as those with 84 active pills, often use 20 µg EE and 100 µg levonorgestrel per pill. These formulations reduce the number of withdrawal bleeding episodes and use low-dose estrogen even during the pill-free interval to minimize unscheduled bleeding 34.
Variability in Estrogen Levels Among Users
Despite standardized dosing, actual estrogen levels in the blood can vary widely between individuals and even from day to day in the same person. This variability is due to differences in metabolism and absorption, making it difficult to predict exact hormone levels for any given user .
Comparison with Other Delivery Methods
Transdermal patches, such as Ortho Evra®, deliver estrogen differently than oral pills. Studies comparing the Ortho Evra® patch to the Ortho-Cyclen® pill show differences in how estrogen is absorbed and maintained in the body, with patches generally providing more consistent hormone levels over time .
Health Considerations and Trends
The trend toward lower estrogen doses in birth control pills is driven by the desire to reduce side effects, especially the risk of blood clots, which is primarily associated with the estrogen component. Ethinyl estradiol is more potent and longer-lasting than natural estradiol, which can increase clotting risk. As a result, formulations with more than 50 µg EE have not been available in the U.S. since 1988 . Newer research is exploring alternative estrogens, such as estetrol, which may have a lower risk profile .
Conclusion
Estrogen levels in birth control pills have decreased dramatically over the decades, with most modern pills containing 35 µg or less of ethinyl estradiol, and some ultra-low dose options at 15–20 µg. The choice of pill and estrogen dose depends on balancing contraceptive effectiveness, side effect profiles, and individual health risks. Ongoing research and new formulations continue to improve safety and user satisfaction 2346+1 MORE.
Sources and full results
Most relevant research papers on this topic
[How to distinguish 2-phase (sequential) steroid contraceptives].
Norbiogest (Spofa) is estrogen dominant in the first half of the cycle and progesterone dominant in the second half, while Tri-Ervonum (Glaxo) has potent estrogen activity at.1mg/day throughout the cycle.
Los nuevos anticonceptivos orales combinados de ultra baja dosis
Ultra low dose oral contraceptives, such as ethinyl estradiol combination 15 ug plus 60 ug of gestodene, have been developed to reduce cardiovascular risks and thromboembolics while maintaining birth-control effectiveness.
DOI